Fortrea Holdings Inc. (FTRE) stock
FTRENasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/3056% above fair value
$19.59−0.20 (-1.01%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Fortrea ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Fortrea's ebitda for the twelve months ending Sep 30, 2026 was $91.50M. For fiscal 2025 it was -$794.60M. The highest annual figure on record is $280.70M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$794.60M | – |
| FY2024 | Dec 31, 2024 | -$75.00M | -157.7% |
| FY2023 | Dec 31, 2023 | $130.00M | -53.7% |
| FY2022 | Dec 31, 2022 | $280.70M | +0.0% |
| FY2021 | Dec 31, 2021 | $280.60M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $35.00M | +218.2% |
| Q2 FY2026 | Jun 30, 2026 | $34.40M | – |
| Q1 FY2026 | Mar 31, 2026 | $16.40M | – |
| Q4 FY2025 | Dec 31, 2025 | $5.70M | – |
| Q3 FY2025 | Sep 30, 2025 | $11.00M | +243.8% |
| Q2 FY2025 | Jun 30, 2025 | -$310.70M | – |
| Q1 FY2025 | Mar 31, 2025 | -$500.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$34.80M | -8800.0% |
| Q3 FY2024 | Sep 30, 2024 | $3.20M | -90.3% |
| Q2 FY2024 | Jun 30, 2024 | -$29.50M | -153.6% |
| Q1 FY2024 | Mar 31, 2024 | -$13.90M | -137.4% |
| Q4 FY2023 | Dec 31, 2023 | $400.00K | -99.0% |
| Q3 FY2023 | Sep 30, 2023 | $33.10M | -63.9% |
| Q2 FY2023 | Jun 30, 2023 | $55.00M | -41.9% |
| Q1 FY2023 | Mar 31, 2023 | $37.20M | – |
| Q4 FY2022 | Dec 31, 2022 | $38.20M | – |
| Q3 FY2022 | Sep 30, 2022 | $91.60M | – |
| Q2 FY2022 | Jun 30, 2022 | $94.60M | – |
See a number that looks wrong?